The authors reply
- PMID: 30444823
- PMCID: PMC6410742
- DOI: 10.1097/CCM.0000000000003453
The authors reply
Comment on
-
Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism.Crit Care Med. 2018 Oct;46(10):1617-1625. doi: 10.1097/CCM.0000000000003288. Crit Care Med. 2018. PMID: 29979222 Free PMC article.
-
Half-Dose Versus Full-Dose Alteplase Therapy in Pulmonary Embolism: Does Half Dose Really Lose?Crit Care Med. 2018 Dec;46(12):e1223-e1224. doi: 10.1097/CCM.0000000000003384. Crit Care Med. 2018. PMID: 30444822 No abstract available.
References
-
- Jin QI, Luo Q, Zhao Z, et al. Half-Dose Versus Full-Dose Alteplase Therapy in Pulmonary Embolism: Does Half-Dose Really Lose? Crit Care Med 2018. - PubMed
-
- Konstantinides SV, Vicaut E, Danays T, et al. Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. J Am Coll Cardiol 2017;69(12):1536–1544. - PubMed
-
- Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014;370(15):1402–1411. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources